The pharmaceutical landscape has recently seen a significant advancement with the US Food and Drug Administration (FDA) granting approval for Lynavoy (linerixibat), a novel therapy targeting cholestatic pruritus in adults diagnosed with primary biliary cholangitis (PBC). This approval represents the first dedicated treatment for this debilitating internal itch condition in the United States, offering hope for patients who have struggled with limited options.
Primary biliary cholangitis is a rare autoimmune liver disease in which bile ducts in the liver gradually become damaged. Over time, this can lead to a buildup of bile acids in the bloodstream. Excess bile acids are believed to be a key factor in cholestatic pruritus, an internal itch that cannot be alleviated by scratching. This condition affects up to 89% of patients living with PBC and can significantly impair quality of life. Symptoms often include severe itching, sleep disturbances, fatigue, and in some cases, patients may even require liver transplantation despite the absence of full liver failure.
Cholestatic pruritus is particularly challenging because it can persist regardless of disease stage or biochemical control. Patients often describe it as an intense, chronic itch that disrupts daily activities and emotional well-being. Until recently, there were very few treatment options specifically developed to address this symptom.
Lynavoy, scientifically known as linerixibat, is an oral ileal bile acid transporter (IBAT) inhibitor. By blocking the reuptake of bile acids in the small intestine, Lynavoy reduces circulating bile acids that contribute to cholestatic pruritus. The medication targets multiple mediators of itch and represents a targeted approach for managing this challenging symptom in PBC patients.
Lynavoy has been granted Orphan Drug Designation in the United States, the European Union, and Japan, highlighting its status as a therapy addressing a rare disease with significant unmet medical needs. Additionally, the drug is under priority review in China, with marketing applications ongoing in multiple regions including the EU, UK, Canada, and China.
The approval of Lynavoy is based on the results of the global GLISTEN phase III trial, a double-blind, randomized, placebo-controlled study designed to evaluate both the efficacy and safety of the therapy. The trial included adult PBC patients suffering from cholestatic pruritus.
The GLISTEN trial demonstrated significant and rapid improvements in patients' symptoms. By week two, participants receiving Lynavoy reported meaningful reductions in itch severity, which were sustained over 24 weeks. The study also showed improvements in sleep quality disrupted by severe itching. On a 0-10 numerical rating scale for the worst itch, the treatment group achieved statistically significant reductions compared to placebo.
The safety profile of Lynavoy was consistent with prior studies. The most common side effects included mild to moderate diarrhea and abdominal pain. In the trial, 4% of patients discontinued treatment due to diarrhea, compared to less than 1% in the placebo group. Abdominal pain led to treatment discontinuation in 4% of participants, while no placebo patients discontinued for this reason.
Several experts and patient advocates have commented on the significance of Lynavoy’s approval.
Kaivan Khavandi, Senior Vice President and Head of Respiratory, Immunology & Inflammation Research at GSK, emphasized that this approval provides a much-needed treatment option that offers rapid and sustained relief from the debilitating effects of cholestatic pruritus. According to him, this is the first liver-targeted medication from GSK’s pipeline to gain approval, highlighting the company’s commitment to innovation in liver disease therapies.
Christopher Bowlus, M.D., Lena Valente Professor and Chief of Gastroenterology and Hepatology at the University of California Davis, remarked that the availability of linerixibat creates an important opportunity to improve the lives of PBC patients suffering from uncontrolled and severe itch. He noted that the FDA’s approval marks a major milestone in addressing this previously neglected area of care.
Carol Roberts, President of The PBCers Organization, shared that the impact of cholestatic pruritus has been historically underestimated and overlooked. She emphasized that Lynavoy offers new hope for patients who have long awaited a dedicated therapy for chronic itch.
The availability of Lynavoy is a breakthrough for PBC patients suffering from cholestatic pruritus. Until now, symptom management options were limited, often leaving patients to cope with persistent itch and its associated complications, including fatigue, emotional distress, and sleep disruption. With Lynavoy, patients now have access to a therapy designed specifically to target the underlying mechanisms of cholestatic pruritus, rather than only addressing symptoms superficially.
The rapid onset of relief observed in clinical trials means that patients may experience improvements in quality of life within weeks of starting treatment. The sustained effects over 24 weeks also suggest that long-term management of itch is feasible with this therapy.
GSK announced a licensing agreement with Alfasigma S.p.A. in March 2026, granting the company worldwide exclusive rights to develop, manufacture, and commercialize linerixibat. This transaction remains ongoing and is subject to customary regulatory approvals, including those required under the Hart-Scott-Rodino Act in the United States.
The regulatory pathway for Lynavoy is also progressing internationally. In addition to its approval in the United States, applications are under review in the European Union, United Kingdom, Canada, and China, signaling potential global availability in the near future.
GSK continues to expand its research in hepatology, focusing on fibro-inflammatory liver conditions such as chronic hepatitis B, metabolic dysfunction-associated steatohepatitis, alcohol-associated liver disease, and other rare liver disorders. The approval of Lynavoy demonstrates the company’s commitment to developing meaningful treatments that improve patient outcomes in areas of high unmet need.
By leveraging advanced technologies and insights into the immune system, GSK aims to deliver therapies that address the underlying drivers of liver disease rather than only treating symptoms. This approach could pave the way for more targeted, effective interventions in hepatology in the coming years.
While Lynavoy offers hope, patients should be aware that it is a prescription medication that requires evaluation by a healthcare professional. Clinicians will consider individual patient factors, including disease stage, previous treatments, and comorbid conditions, to determine whether Lynavoy is appropriate. Patients should report any adverse reactions, particularly gastrointestinal symptoms such as diarrhea or abdominal pain, to their healthcare provider.
It is also important for patients to maintain regular follow-up visits to monitor treatment response and adjust therapy as needed. Healthcare providers may recommend additional supportive care measures to improve overall quality of life, including sleep hygiene strategies and lifestyle modifications to manage fatigue.
The approval of Lynavoy is expected to transform the therapeutic landscape for PBC, especially for patients suffering from cholestatic pruritus. Historically, treatment options have focused on managing liver damage or using medications that provide limited relief from itch. With a targeted therapy now available, patients have a more effective solution for a symptom that has long been overlooked.
The global phase III clinical trial data supporting Lynavoy may also encourage further research into bile acid transport inhibitors for other liver diseases or conditions associated with chronic itch. This could lead to broader therapeutic applications beyond PBC.
Lynavoy’s approval marks a landmark development in the management of cholestatic pruritus in primary biliary cholangitis. The therapy addresses a critical unmet medical need, providing rapid and sustained relief from a debilitating symptom that affects the majority of PBC patients. Clinical trial evidence, regulatory recognition, and expert endorsements all underscore the significance of this advancement.
As global regulatory reviews continue and Lynavoy becomes more widely available, patients living with PBC may soon experience meaningful improvements in quality of life. This approval not only represents a breakthrough for individuals affected by this rare disease but also highlights the ongoing innovation in hepatology research aimed at improving patient outcomes worldwide.
This article is for informational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Always consult a healthcare professional before starting or changing any medication or therapy.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.